Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus
暂无分享,去创建一个
H. Achdout | N. Paran | N. Erez | T. Israely | S. Melamed | B. Politi | H. Tamir | Einat B. Vitner | Y. Yahalom-Ronen | R. Avraham | Lilach Cherry | Einat. B. Vitner
[1] V. Botosso,et al. SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network , 2020, Memorias do Instituto Oswaldo Cruz.
[2] Natacha S. Ogando,et al. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology , 2020, bioRxiv.
[3] Joy Y. Feng,et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.
[4] M. Kester,et al. Glucosylceramide synthase maintains influenza virus entry and infection , 2020, PloS one.
[5] Carolina L. Bellera,et al. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics , 2019, Expert opinion on drug discovery.
[6] M. Kester,et al. Glucosylceramidase Maintains Influenza Virus Infection by Regulating Endocytosis , 2019, Journal of Virology.
[7] R. Kuhn,et al. Dynamic remodeling of lipids coincides with dengue virus replication in the midgut of Aedes aegypti mosquitoes , 2018, PLoS pathogens.
[8] F. Bushman,et al. A role for glycolipid biosynthesis in severe fever with thrombocytopenia syndrome virus entry , 2017, PLoS pathogens.
[9] L. Riboni,et al. Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids , 2017, Advances in Therapy.
[10] S. Alves,et al. Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders , 2016, International journal of molecular sciences.
[11] H. Low,et al. Cytomegalovirus Restructures Lipid Rafts via a US28/CDC42-Mediated Pathway, Enhancing Cholesterol Efflux from Host Cells. , 2016, Cell reports.
[12] D. Leshkowitz,et al. Induction of the type I interferon response in neurological forms of Gaucher disease , 2016, Journal of Neuroinflammation.
[13] Ying Sun,et al. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[14] R. Dwek,et al. Iminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-Glucosidases—Not Glycolipid Processing Enzymes , 2016, PLoS neglected tropical diseases.
[15] J. Souza-Neto,et al. A Lipidomics Approach in the Characterization of Zika-Infected Mosquito Cells: Potential Targets for Breaking the Transmission Cycle , 2016, PloS one.
[16] B. Wang,et al. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease , 2015, Molecular medicine.
[17] S. Packman,et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. , 2015, JAMA.
[18] J. Miller,et al. Strain-specific antiviral activity of iminosugars against human influenza A viruses , 2014, The Journal of antimicrobial chemotherapy.
[19] K. Konan,et al. Modulation of Hepatitis C Virus Genome Replication by Glycosphingolipids and Four-Phosphate Adaptor Protein 2 , 2014, Journal of Virology.
[20] Frances M. Platt,et al. Sphingolipid lysosomal storage disorders , 2014, Nature.
[21] S. Rozen,et al. Lipidomics identifies a requirement for peroxisomal function during influenza virus replication[S] , 2014, Journal of Lipid Research.
[22] R. Dwek,et al. Liposome-Mediated Delivery of Iminosugars Enhances Efficacy against Dengue Virus In Vivo , 2012, Antimicrobial Agents and Chemotherapy.
[23] R. Scheule,et al. Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease , 2012, PloS one.
[24] Jinhong Chang,et al. Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection. , 2012, Journal of medicinal chemistry.
[25] D. Alonzi,et al. Inhibitors of Endoplasmic Reticulum α-Glucosidases Potently Suppress Hepatitis C Virus Virion Assembly and Release , 2010, Antimicrobial Agents and Chemotherapy.
[26] Shayman Ja. ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease. , 2010 .
[27] N. Zitzmann,et al. Targeting a host process as an antiviral approach against dengue virus. , 2010, Trends in Microbiology.
[28] D. Burton,et al. N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery , 2008, AIDS.
[29] H. Achdout,et al. Influenza Virus Infection Augments NK Cell Inhibition through Reorganization of Major Histocompatibility Complex Class I Proteins , 2008, Journal of Virology.
[30] J. Shayman,et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. , 2007, Molecular genetics and metabolism.
[31] Seng H. Cheng,et al. Inhibiting Glycosphingolipid Synthesis Improves Glycemic Control and Insulin Sensitivity in Animal Models of Type 2 Diabetes , 2007, Diabetes.
[32] Yasuo Suzuki,et al. Suppression of the biosynthesis of cellular sphingolipids results in the inhibition of the maturation of influenza virus particles in MDCK cells. , 2006, Biological & pharmaceutical bulletin.
[33] E. Clercq. Antivirals and antiviral strategies , 2004, Nature Reviews Microbiology.
[34] R. Dwek,et al. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: Therapeutic implications , 2001, Hepatology.
[35] P. Desprès,et al. α-Glucosidase Inhibitors Reduce Dengue Virus Production by Affecting the Initial Steps of Virion Morphogenesis in the Endoplasmic Reticulum , 2000, Journal of Virology.
[36] R. Dwek,et al. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[37] R. Dwek,et al. N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure , 1996, Journal of virology.
[38] R. Dwek,et al. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. , 1994, The Journal of biological chemistry.
[39] C. E.. WHO Coronavirus Disease (COVID-19) Dashboard , 2020 .
[40] P. Maison-Blanche,et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. , 2017, European journal of internal medicine.
[41] A. Futerman,et al. Neuronal forms of Gaucher disease. , 2013, Handbook of experimental pharmacology.
[42] E. De Clercq,et al. Antivirals and antiviral strategies. , 2004, Nature reviews. Microbiology.